FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2973889452> ?p ?o ?g. }

• W2973889452 endingPage "1417" @default.
• W2973889452 startingPage "1407" @default.
• W2973889452 abstract "Abstract Background This study compares well-being, recurrences, and deaths of early-stage cutaneous melanoma patients in follow-up, as recommended in the Dutch guideline, with that of patients in a stage-adjusted reduced follow-up schedule, 3 years after diagnosis, as well as costs. Methods Overall, 180 eligible pathological American Joint Committee on Cancer (AJCC) stage IB–IIC, sentinel node staged, melanoma patients (response rate = 87%, 48% male, median age 57 years), randomized into a conventional (CSG, n = 93) or experimental (ESG, n = 87) follow-up schedule group, completed patient-reported outcome measures (PROMs) at diagnosis (T1): State-Trait Anxiety Inventory–State version (STAI-S), Cancer Worry Scale (CWS), Impact of Event Scale (IES), and RAND-36 (Mental and Physical Component scales [PCS/MCS]). Three years later (T3), 110 patients (CSG, n = 56; ESG, n = 54) completed PROMs, while 42 declined (23%). Results Repeated measures analyses of variance (ANOVAs) showed a significant group effect on the IES ( p = 0.001) in favor of the ESG, and on the RAND-36 PCS ( p = 0.02) favoring the CSG. Mean IES and CWS scores decreased significantly over time, while those on the RAND-36 MCS and PCS increased. Effect sizes were small. Twenty-five patients developed a recurrence or second primary melanoma, of whom 13 patients died within 3 years. Cox proportional hazards models showed no differences between groups in recurrence-free survival (hazard ratio [HR] 0.71 [0.32–1.58]; p = 0.400) and disease-free survival (HR 1.24 [0.42–3.71]; p = 0.690). Costs per patient after 3 years (computed for 77.3% of patients) were 39% lower in the ESG. Conclusion These results seemingly support the notion that a stage-adjusted reduced follow-up schedule forms an appropriate, safe, and cost-effective alternative for pathological AJCC stage IB–IIC melanoma patients to the follow-up regimen as advised in the current melanoma guideline." @default.
• W2973889452 created "2019-09-26" @default.
• W2973889452 creator A5020107252 @default.
• W2973889452 creator A5021727928 @default.
• W2973889452 creator A5035443482 @default.
• W2973889452 creator A5061242738 @default.
• W2973889452 creator A5071761951 @default.
• W2973889452 creator A5082112287 @default.
• W2973889452 creator A5084791870 @default.
• W2973889452 date "2019-09-18" @default.
• W2973889452 modified "2023-10-04" @default.
• W2973889452 title "The MELFO Study: A Multicenter, Prospective, Randomized Clinical Trial on the Effects of a Reduced Stage-Adjusted Follow-Up Schedule on Cutaneous Melanoma IB–IIC Patients—Results After 3 Years" @default.
• W2973889452 cites W1500801700 @default.
• W2973889452 cites W16848520 @default.
• W2973889452 cites W1956950232 @default.
• W2973889452 cites W1969931779 @default.
• W2973889452 cites W1973400651 @default.
• W2973889452 cites W1982577230 @default.
• W2973889452 cites W2021786774 @default.
• W2973889452 cites W2024033132 @default.
• W2973889452 cites W2025518136 @default.
• W2973889452 cites W2046736751 @default.
• W2973889452 cites W2053869839 @default.
• W2973889452 cites W2066358461 @default.
• W2973889452 cites W2071868318 @default.
• W2973889452 cites W2100901698 @default.
• W2973889452 cites W2104553571 @default.
• W2973889452 cites W2104695445 @default.
• W2973889452 cites W2117532865 @default.
• W2973889452 cites W2125018505 @default.
• W2973889452 cites W2145956339 @default.
• W2973889452 cites W2147070212 @default.
• W2973889452 cites W2253428225 @default.
• W2973889452 cites W2407048296 @default.
• W2973889452 cites W2586291003 @default.
• W2973889452 cites W2671769150 @default.
• W2973889452 cites W2781771775 @default.
• W2973889452 cites W2782113716 @default.
• W2973889452 cites W4211223138 @default.
• W2973889452 cites W840575386 @default.
• W2973889452 doi "https://doi.org/10.1245/s10434-019-07825-7" @default.
• W2973889452 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7138761" @default.
• W2973889452 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31535302" @default.
• W2973889452 hasPublicationYear "2019" @default.
• W2973889452 type Work @default.
• W2973889452 sameAs 2973889452 @default.
• W2973889452 citedByCount "28" @default.
• W2973889452 countsByYear W29738894522019 @default.
• W2973889452 countsByYear W29738894522020 @default.
• W2973889452 countsByYear W29738894522021 @default.
• W2973889452 countsByYear W29738894522022 @default.
• W2973889452 countsByYear W29738894522023 @default.
• W2973889452 crossrefType "journal-article" @default.
• W2973889452 hasAuthorship W2973889452A5020107252 @default.
• W2973889452 hasAuthorship W2973889452A5021727928 @default.
• W2973889452 hasAuthorship W2973889452A5035443482 @default.
• W2973889452 hasAuthorship W2973889452A5061242738 @default.
• W2973889452 hasAuthorship W2973889452A5071761951 @default.
• W2973889452 hasAuthorship W2973889452A5082112287 @default.
• W2973889452 hasAuthorship W2973889452A5084791870 @default.
• W2973889452 hasBestOaLocation W29738894521 @default.
• W2973889452 hasConcept C126322002 @default.
• W2973889452 hasConcept C141071460 @default.
• W2973889452 hasConcept C146357865 @default.
• W2973889452 hasConcept C151730666 @default.
• W2973889452 hasConcept C168563851 @default.
• W2973889452 hasConcept C207103383 @default.
• W2973889452 hasConcept C2777658100 @default.
• W2973889452 hasConcept C44249647 @default.
• W2973889452 hasConcept C502942594 @default.
• W2973889452 hasConcept C50382708 @default.
• W2973889452 hasConcept C71924100 @default.
• W2973889452 hasConcept C86803240 @default.
• W2973889452 hasConceptScore W2973889452C126322002 @default.
• W2973889452 hasConceptScore W2973889452C141071460 @default.
• W2973889452 hasConceptScore W2973889452C146357865 @default.
• W2973889452 hasConceptScore W2973889452C151730666 @default.
• W2973889452 hasConceptScore W2973889452C168563851 @default.
• W2973889452 hasConceptScore W2973889452C207103383 @default.
• W2973889452 hasConceptScore W2973889452C2777658100 @default.
• W2973889452 hasConceptScore W2973889452C44249647 @default.
• W2973889452 hasConceptScore W2973889452C502942594 @default.
• W2973889452 hasConceptScore W2973889452C50382708 @default.
• W2973889452 hasConceptScore W2973889452C71924100 @default.
• W2973889452 hasConceptScore W2973889452C86803240 @default.
• W2973889452 hasIssue "5" @default.
• W2973889452 hasLocation W29738894521 @default.
• W2973889452 hasLocation W29738894522 @default.
• W2973889452 hasLocation W29738894523 @default.
• W2973889452 hasLocation W29738894524 @default.
• W2973889452 hasOpenAccess W2973889452 @default.
• W2973889452 hasPrimaryLocation W29738894521 @default.
• W2973889452 hasRelatedWork W2003938723 @default.
• W2973889452 hasRelatedWork W2047967234 @default.
• W2973889452 hasRelatedWork W2118496982 @default.
• W2973889452 hasRelatedWork W2364998975 @default.
• W2973889452 hasRelatedWork W2369162477 @default.
• W2973889452 hasRelatedWork W2439875401 @default.

• next